表紙
市場調查報告書

免疫學的生物相似藥

Biosimilars in Immunology

出版商 GlobalData 商品編碼 929733
出版日期 內容資訊 英文 137 Pages
訂單完成後即時交付
價格
免疫學的生物相似藥 Biosimilars in Immunology
出版日期: 2020年02月28日內容資訊: 英文 137 Pages
簡介

本報告提供全球主要9個國家(美國、歐洲 (法國、德國、義大利、西班牙、英國)、日本、印度、韓國) 中,免疫藥的生物相似藥的市場相關分析,技術、產品的概要,主要的應用領域的概要,主要企業的簡介,主要市場競爭策略等調查,各國市場結構和法規、認證體制,潛在的市場規模預測,今後的技術開發、市場發展的方向性等資訊,為您概述為以下內容。

第1章 簡介

第2章 摘要整理

第3章 簡介

  • 生物相似藥是什麼
  • 免疫學生物相似藥:開發的時間軸
  • 全球主要國家上市的,開發平台上的免疫生物相似藥

第4章 世界各地的生物相似藥法規途徑

  • 生物相似藥的法規途徑
  • 美國的生物相似藥法規途徑
  • 歐洲的生物相似藥法規途徑
  • 日本的生物相似藥法規途徑
  • 韓國的生物相似藥法規途徑
  • 印度的生物相似藥法規途徑

第5章 生物相似藥市場:各國的趨勢 (主要國家)

  • 生物相似藥市場趨勢預測:各國 (主要國家)
  • 美國的生物相似藥市場潛力
  • 歐洲的生物相似藥市場潛力
  • 日本的生物相似藥市場潛力
  • 韓國的生物相似藥市場潛力
  • 印度的生物相似藥市場潛力

第6章 免疫學的重要應用領域

  • 免疫學的生技藥品的應用領域
  • 類風濕性關節炎
  • 乾癬性關節炎
  • 軸性脊椎關節炎
  • 潰瘍性大腸炎
  • 克隆氏症
  • 斑塊乾癬

第7章 主要企業

  • 製造商評價的重要性
  • Sandoz
  • Celltrion
  • Amgen
  • Mylan and Biocon
  • Pfizer
  • Biogen

第8章 在生物相似藥:臨床方面、商業方面的主要概念

  • 降低成本和市場進入
  • 患者的種類
  • 處方藥的分配
  • 生物相似藥性和兼容性
  • 品牌的偏好
  • 資料的外插

第9章 生物相似藥、製造商機會

  • 為了擴大生物相似藥的接種力的策略
  • 價格的市場差異化
  • 革新的市場差異化

第10章 附錄

目錄
Product Code: GDHCHT048

"GlobalData's Biosimilars in Immunology Thematic Analysis report combines key opinion leader insight and interviews with payers in the US, France, Germany, Italy, Spain, the UK, Japan, India and South Korea to provide an in-depth review of the biosimilars market for major autoimmune diseases."

The report includes an assessment of ongoing clinical trials, the geographical location of trial sponsors, discussion of the key players in the medical marijuana space as well as insights from industry experts discussing market challenges and considerations of stakeholders in the arena."

Europe leads the way for immunology biosimilars in the 7MM, and India is at the forefront in the emerging markets. In terms of immunology biosimilar penetration, the 5EU and India demonstrate the highest favorability towards uptake of biosimilars.

Japan and South Korea have an intermediate biosimilar penetration index, while the US market is the least favorable towards biosimilars. Pricing is a key issue for expensive-to-develop biosimilars entering an increasingly crowded autoimmune disease market.Biosimilars are intended to relieve healthcare-associated cost burden; however, the economic effects of incorporating them into clinical practice are unclear, due to increased time and staff costs required for switching patients onto biosimilars.

Pricing can be a differentiating strategy among different biosimilars and larger discounts over originator brands can boost greater uptake of specific biosimilars. Quotas dictate prescribing patterns in the 5EU; however, physicians show concern about switching to a biosimilar from the originator brand. The majority of KOLs interviewed by GlobalData indicated that they used biosimilars mostly for new patients. KOLs also cited reluctance to switch existing patients to biosimilars, highlighting that they did not want to change a biologic treatment that was working for the patient.

Other reasons against switching included lack of incentives for physicians, lack of switching data, and nocebo effects.Biogen, Sandoz, Pfizer, and Amgen are dominating the immunology biosimilars field. The immunology biosimilars space is dominated in developed markets by established brand names, including Biogen, Sandoz, Pfizer, and Amgen.

In India and South Korea, major biosimilar players include Celltrion, Cipla, and Zydus Cadila.

Scope

Components of the report include -

  • Introduction to*Biosimilars in Immunology*-*Defining biosimilars in immunology and discussing the history of drugs approved across the 9MM.
  • Assessment of Marketed and Pipeline Products*- An overview of biosimilar products on the market and drugs currently in clinical development.
  • Regulatory Strategies*-*Overview of biosimilar regulatory strategies by country.
  • Market Dynamics - Overview of biosimilar market dynamics by country.
  • Focus Indications*and Market Potential - In-depth assessment of biosimilars in major autoimmune indications, market potential as well as drivers and barriers to uptake.

Reasons to Buy

  • Key Players - In-depth assessment of key players in the space across the 9MM
  • Key Clinical and Commercial Concepts*- An examination of key clinical and commercial concepts in the biosimilars in immunology space, based on KOL and payer insights.
  • Pricing and reimbursement infrastructure and challenges are examined.
  • Future Opportunities*- Overview of future strategies recommended by KOLs and payers for boosting biosimilar uptake is discussed.

TABLE OF CONTENTS

1. Preface

  • 1.1 Related Reports
  • 1.2 Upcoming Reports
  • 1.3 Abbreviations

2. Executive Summary

  • 2.1 Key Findings
  • 2.2 KOL and Payer Insights

3. Introduction

  • 3.1 What Is a Biosimilar?
  • 3.2 Timeline of Immunology Biosimilar Development
  • 3.3 Marketed and Pipeline Immunology Biosimilars in the 9MM

4. Biosimilar Regulatory Pathways Across Geographies

  • 4.1 Biosimilar Regulatory Pathways
  • 4.2 US Biosimilar Regulatory Pathway
  • 4.3 EU Biosimilar Regulatory Pathway
  • 4.4 Japan Biosimilar Regulatory Pathway
  • 4.5 South Korea Biosimilar Regulatory Pathway
  • 4.6 India Biosimilar Regulatory Pathway

5. Biosimilar Country-Specific Dynamics, 9MM

  • 5.1 Biosimilar Country-Specific Dynamics, 9MM
  • 5.2 US Biosimilar Market Potential
  • 5.3 5EU Biosimilar Market Potential
  • 5.4 Japan Biosimilar Market Potential
  • 5.5 South Korea Biosimilar Market Potential
  • 5.6 India Biosimilar Market Potential

6. Important Indications in Immunology

  • 6.1 Biologic Use in Immunology
  • 6.2 Rheumatoid Arthritis
  • 6.3 Psoriatic Arthritis
  • 6.4 Axial Spondyloarthritis
  • 6.5 Ulcerative Colitis
  • 6.6 Crohn's Disease
  • 6.7 Plaque Psoriasis

7. Major Players

  • 7.1 Importance of Manufacturer Reputation
  • 7.2 Sandoz
  • 7.3 Celltrion
  • 7.4 Amgen
  • 7.5 Mylan and Biocon
  • 7.6 Pfizer
  • 7.7 Biogen

8. Biosimilars - Key Clinical and Commercial Concepts

  • 8.1 Cost Savings and Market Access
  • 8.2 Patient Type
  • 8.3 Prescription Quotas
  • 8.4 Biosimilarity and Interchangeability
  • 8.5 Brand Preference
  • 8.6 Extrapolation of Data

9. Opportunities for Biosimilar Manufacturers

  • 9.1 Strategies for Increasing Uptake of Biosimilars
  • 9.2 Differentiation by Pricing
  • 9.3 Differentiation by Innovation

10. Appendix

  • 10.1 Primary Research
  • 10.2 Sources
  • 10.3 About the Authors
  • 10.4 About GlobalData
  • 10.5 Contact Us
  • 10.6 Disclaimer